Altered Sphingolipid Metabolism and its Interaction With the Intestinal Microbiome Is Another Key to the Pathogenesis of Inflammatory Bowel Disease
С. И. Ситкин, Juris Pokrotnieks(Pauls Stradiņš Clinical University Hospital), Elena Demyanova(State Research Institute of Highly Pure Biopreparations), Timur Vakhitov(Institute of Experimental Medicine)
Cited by 6
Related Papers
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
|The Lancet. Gastroenterology & hepatology|2023|72
Whole-Genome Sequencing of Lactobacillus helveticus D75 and D76 Confirms Safety and Probiotic Potential
|Microorganisms|2020|43
Polypeptide Self-Assembled Nanoparticles as Delivery Systems for Polymyxins B and E
|Pharmaceutics|2020|35
Hyaluronan/colistin polyelectrolyte complexes: Promising antiinfective drug delivery systems
|International Journal of Biological Macromolecules|2021|31
Hyaluronan/Diethylaminoethyl Chitosan Polyelectrolyte Complexes as Carriers for Improved Colistin Delivery
|International Journal of Molecular Sciences|2021|25